Adeno-associated virus capsid serotype identification: Analytical methods development and application

Journal of Virological Methods

Volumn 159, Issue 2, 2009, Pages 167-177

  Van Vliet, Kim ^a   Mohiuddin, Yasmin ^a   McClung, Scott ^b   Blouin, Veronique ^c   Rolling, Fabienne ^c   Moullier, Philippe ^a,c   Agbandje McKenna, Mavis ^a   Snyder, Richard O ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c HÔTEL DIEU   (France)

Author keywords

AAV; Adeno associated virus; Capsid; Mass spectrometry; Retina; Serotype identity

Indexed keywords

AMINO ACID; CYCLIC GMP; MONOCLONAL ANTIBODY;

ADENO ASSOCIATED VIRUS; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA BASE; GENE TRANSFER; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SENSITIVITY AND SPECIFICITY; SEROTYPE; VIRUS CAPSID; VIRUS IDENTIFICATION; VIRUS MUTATION; VIRUS RECOMBINANT; WILD TYPE;

CAPSID PROTEINS; CELL LINE; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY; SEROTYPING;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 67349159102     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.03.020     Document Type: Article

References (69)

1. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., Viswanathan A., Holder G.E., Stockman A., Tyler N., Petersen-Jones S., Bhattacharya S.S., Thrasher A.J., Fitzke F.W., Carter B.J., Rubin G.S., Moore A.T., and Ali R.R. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008) 2231-2239
2. Chen C.L., Jensen R.L., Schnepp B.C., Connell M.J., Shell R., Sferra T.J., Bartlett J.S., Clark K.R., and Johnson P.R. Molecular characterization of adeno-associated viruses infecting children. J. Virol. 79 (2005) 14781-14792
3. Chiorini J.A., Yang L., Liu Y., Safer B., and Kotin R.M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71 (1997) 6823-6833
4. Cideciyan A.V., Aleman T.S., Boye S.L., Schwartz S.B., Kaushal S., Roman A.J., Pang J.-J., Sumaroka A., Windsor E.A.M., Wilson J.M., Flotte T.R., Fishman G.A., Heon E., Stone E.M., Byrne B.J., Jacobson S.G., and Hauswirth W.W. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 15112-15117
5. Clark K.R., Voulgaropoulou F., and Johnson P.R. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 3 (1996) 1124-1132
6. Colquhoun D.R., Schwab K.J., Cole R.N., and Halden R.U. Detection of norovirus capsid protein in authentic standards and in stool extracts by matrix-assisted laser desorption ionization and nanospray mass spectrometry. Appl. Environ. Microbiol. 72 (2006) 2749-2755
7. DiMattia M., Govindasamy L., Levy H.C., Gurda-Whitaker B., Kalina A., Kohlbrenner E., Chiorini J.A., McKenna R., Muzyczka N., Zolotukhin S., and Agbandje-McKenna M. Production, purification, crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 61 (2005) 917-921
8. DiPrimio N., Asokan A., Govindasamy L., Agbandje-McKenna M., and Samulski R.J. Surface loop dynamics in adeno-associated virus capsid assembly. J. Virol. 82 (2008) 5178-5189
9. Duisit G., Conrath H., Saleun S., Folliot S., Provost N., Cosset F.L., Sandrin V., Moullier P., and Rolling F. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol. Ther. 6 (2002) 446-454
10. European Pharmacopeia, 2002. Directorate for the Quality of Medicines of the Council of Europe. 4th ed., pp. 58-60 (2.2.43).
11. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., and Wilson J.M. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78 (2004) 6381-6388
12. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11854-11859
13. Govindasamy L., Padron E., McKenna R., Muzyczka N., Kaludov N., Chiorini J.A., and Agbandje-McKenna M. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80 (2006) 11556-11570
14. Grimm D., Kern A., Pawlita M., Ferrari F., Samulski R., and Kleinschmidt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6 (1999) 1322-1330
15. Grimm D., Kay M.A., and Kleinschmidt J.A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7 (2003) 839-850
16. Grimm D., Lee J.S., Wang L., Desai T., Akache B., Storm T.A., and Kay M.A. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008) 5887-5911
17. Hauswirth W., Aleman T.S., Kaushal S., Cideciyan A.V., Schwartz S.B., Wang L., Conlon T., Boye S.L., Flotte T.R., Byrne B., and Jacobson S.G. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a Phase I trial. Hum. Gene Ther. 19 (2008) 979-990
18. Hermonat P.L., and Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 6466-6470
19. Hernandez Y.J., Wang J., Kearns W.G., Loiler S., Poirier A., and Flotte T.R. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73 (1999) 8549-8558
20. Kattenhorn L.M., Mills R., Wagner M., Lomsadze A., Makeev V., Borodovsky M., Ploegh H.L., and Kessler B.M. Identification of proteins associated with murine cytomegalovirus virions. J. Virol. 78 (2004) 11187-11197
21. Keller A., Nesvizhskii A.I., Kolker E., and Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74 (2002) 5383-5392
22. Kern A., Schmidt K., Leder C., Muller O.J., Wobus C.E., Bettinger K., Von der Lieth C.W., King J.A., and Kleinschmidt J.A. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77 (2003) 11072-11081
23. Kronenberg S., Kleinschmidt J.A., and Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2 (2001) 997-1002
24. Kuck D., Kern A., and Kleinschmidt J.A. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140 (2007) 17-24
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
26. Le Meur G., Stieger K., Smith A.J., Weber M., Deschamps J.Y., Nivard D., Mendes-Madeira A., Provost N., Pereon Y., Cherel Y., Ali R.R., Hamel C., Moullier P., and Rolling F. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 14 (2007) 292-303
27. Liu H.C., Soderblom E.J., and Goshe M.B. A mass spectrometry-based proteomic approach to study Marek's Disease Virus gene expression. J. Virol. Methods 135 (2006) 66-75
28. Maaty W.S., Ortmann A.C., Dlakic M., Schulstad K., Hilmer J.K., Liepold L., Weidenheft B., Khayat R., Douglas T., Young M.J., and Bothner B. Characterization of the archaeal thermophile Sulfolobus turreted icosahedral virus validates an evolutionary link among double-stranded DNA viruses from all domains of life. J. Virol. 80 (2006) 7625-7635
29. Maguire A.M., Simonelli F., Pierce E.A., Pugh Jr. E.N., Mingozzi F., Bennicelli J., Banfi S., Marshall K.A., Testa F., Surace E.M., Rossi S., Lyubarsky A., Arruda V.R., Konkle B., Stone E., Sun J., Jacobs J., Dell'Osso L., Hertle R., Ma J.X., Redmond T.M., Zhu X., Hauck B., Zelenaia O., Shindler K.S., Maguire M.G., Wright J.F., Volpe N.J., McDonnell J.W., Auricchio A., High K.A., and Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008) 2240-2248
30. Maheshri N., Koerber J.T., Kaspar B.K., and Schaffer D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24 (2006) 198-204
31. McLaughlin S.K., Collis P., Hermonat P.L., and Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J. Virol. 62 (1988) 1963-1973
32. Mitchell D.A., O'Donnell J., Hare J.T., and Chapman M.S. Serotype-specific detection of adeno-associated virus during laboratory preparation. J. Virol. Methods 136 (2006) 277-282
33. Mori S., Wang L., Takeuchi T., and Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330 (2004) 375-383
34. Moskalenko M., Chen L., van Roey M., Donahue B.A., Snyder R.O., McArthur J.G., and Patel S.D. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74 (2000) 1761-1766
35. Mueller C., and Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15 (2008) 858-863
36. Murray S., Nilsson C.L., Hare J.T., Emmett M.R., Korostelev A., Ongley H., Marshall A.G., and Chapman M.S. Characterization of the capsid protein glycosylation of adeno-associated virus type 2 by high-resolution mass spectrometry. J. Virol. 80 (2006) 6171-6176
37. Muzyczka N., and Warrington Jr. K.H. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 16 (2005) 408-416
38. Nam H.J., Lane M.D., Padron E., Gurda B., McKenna R., Kohlbrenner E., Aslanidi G., Byrne B., Muzyczka N., Zolotukhin S., and Agbandje-McKenna M. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81 (2007) 12260-12271
39. Nesvizhskii A.I., Keller A., Kolker E., and Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75 (2003) 4646-4658
40. Opie S.R., Warrington Jr. K.H., Agbandje-McKenna M., Zolotukhin S., and Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77 (2003) 6995-7006
41. Padron E., Bowman V., Kaludov N., Govindasamy L., Levy H., Nick P., McKenna R., Muzyczka N., Chiorini J.A., Baker T.S., and Agbandje-McKenna M. Structure of adeno-associated virus type 4. J. Virol. 79 (2005) 5047-5058
42. Peden C.S., Burger C., Muzyczka N., and Mandel R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 78 (2004) 6344-6359
43. Petry H., Brooks A., Orme A., Wang P., Liu P., Xie J., Kretschmer P., Qian H.S., Hermiston T.W., and Harkins R.N. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther. 15 (2008) 54-60
44. Prasad K.M., and Trempe J.P. The adeno-associated virus Rep78 protein is covalently linked to viral DNA in a preformed virion. Virology 214 (1995) 360-370
45. Renesto P., Abergel C., Decloquement P., Moinier D., Azza S., Ogata H., Fourquet P., Gorvel J.P., and Claverie J.M. Mimivirus giant particles incorporate a large fraction of anonymous and unique gene products. J. Virol. 80 (2006) 11678-11685
46. Resch W., Hixson K.K., Moore R.J., Lipton M.S., and Moss B. Protein composition of the vaccinia virus mature virion. Virology 358 (2007) 233-247
47. Rutledge E.A., Halbert C.L., and Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72 (1998) 309-319
48. Schmidt M., Grot E., Cervenka P., Wainer S., Buck C., and Chiorini J.A. Identification and characterization of novel adeno-associated virus isolates in ATCC virus stocks. J. Virol. 80 (2006) 5082-5085
49. Schmidt M., Voutetakis A., Afione S., Zheng C., Mandikian D., and Chiorini J.A. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82 (2008) 1399-1406
50. Shen X., Storm T., and Kay M.A. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol. Ther. 15 (2007) 1955-1962
51. Shi W., Hemminki A., and Bartlett J.S. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol. Oncol. 103 (2006) 1054-1062
52. Speir J.A., Bothner B., Qu C., Willits D.A., Young M.J., and Johnson J.E. Enhanced local symmetry interactions globally stabilize a mutant virus capsid that maintains infectivity and capsid dynamics. J. Virol. 80 (2006) 3582-3591
53. Swatkoski S., Russell S., Edwards N., and Fenselau C. Analysis of a model virus using residue-specific chemical cleavage and MALDI-TOF mass spectrometry. Anal. Chem. 79 (2007) 654-658
54. United States Pharmacopeia. The United States Pharmacopeial Convention, 30th ed., vol. 1 (736) (2007) 301-305
55. Van Vliet K., Blouin V., Agbandje-McKenna M., and Snyder R.O. Proteolytic mapping of the adeno-associated virus capsid. Mol. Ther. 14 (2006) 809-821
56. Van Vliet K.M., Blouin V., Brument N., Agbandje-McKenna M., and Snyder R.O. The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 437 (2008) 51-91
57. Vandenberghe L.H., Wang L., Somanathan S., Zhi Y., Figueredo J., Calcedo R., Sanmiguel J., Desai R.A., Chen C.S., Johnston J., Grant R.L., Gao G., and Wilson J.M. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat. Med. 12 (2006) 967-971
58. Walters R.W., Agbandje-McKenna M., Bowman V.D., Moninger T.O., Olson N.H., Seiler M., Chiorini J.A., Baker T.S., and Zabner J. Structure of adeno-associated virus serotype 5. J. Virol. 78 (2004) 3361-3371
59. White K., Buning H., Kritz A., Janicki H., McVey J., Perabo L., Murphy G., Odenthal M., Work L.M., Hallek M., Nicklin S.A., and Baker A.H. Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther. 15 (2008) 443-451
60. Wu P., Xiao W., Conlon T., Hughes J., Agbandje-McKenna M., Ferkol T., Flotte T., and Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74 (2000) 8635-8647
61. Wu Z., Asokan A., Grieger J.C., Govindasamy L., Agbandje-McKenna M., and Samulski R.J. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80 (2006) 11393-11397
62. Xiao X., Xiao W., Li J., and Samulski R.J. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. 71 (1997) 941-948
63. Xiao X., Li J., and Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72 (1998) 2224-2232
64. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., and Chapman M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10405-10410
65. Xie Q., Somasundaram T., Bhatia S., Bu W., and Chapman M.S. Structure determination of adeno-associated virus 2: three complete virus particles per asymmetric unit. Acta Crystallogr. D: Biol. Crystallogr. 59 (2003) 959-970
66. Yea C., Bukh J., Ayers M., Roberts E., Krajden M., and Tellier R. Monitoring of hepatitis C virus quasispecies in chronic infection by matrix-assisted laser desorption ionization-time of flight mass spectrometry mutation detection. J. Clin. Microbiol. 45 (2007) 1053-1057
67. Zaiss A.K., and Muruve D.A. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 15 (2008) 808-816
68. Zhong L., Li B., Mah C.S., Govindasamy L., Agbandje-McKenna M., Cooper M., Herzog R.W., Zolotukhin I., Warrington Jr. K.H., Weigel-Van Aken K.A., Hobbs J.A., Zolotukhin S., Muzyczka N., and Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 7827-7832
69. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites Jr. T.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., and Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167